Rebecca A Hubbard, Ph.D.
University of Pennsylvania School of Medicine
604 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
B.S. (Ecology & Evolution, summa cum laude)
University of Pittsburgh, Pittsburgh, PA, 1999.
University of Edinburgh, Edinburgh, UK, 2001.
M.Sc. (Applied Statistics, with honors)
Oxford University, Oxford, UK, 2002.
University of Washington, Seattle, WA , 2007.
Description of Research ExpertiseDr. Hubbard's research focuses on development and application of statistical methodology for studies using observational data from community medical practice. This work encompasses evaluation of screening and diagnostic test performance, methods for comparative effectiveness studies, and health services research. A wealth of data on healthcare utilization, performance, and outcomes are available from electronic medical records. However, the complex observation scheme giving rise to these data necessitates careful study design and analysis to ensure that inference is valid. Dr. Hubbard’s methodological research emphasizes development of statistical tools for such inference and has been applied to studies of cancer screening, aging and dementia, pharmacoepidemiology, women’s health, and behavioral health.
Selected PublicationsChen L, Chubak J, Yu O, Pocobelli GP, Ziebell RA, Bowles EA, Fujii MM, Sterrett AT, Boggs JM, Ritzwoller DP, Hubbard RA, Boudreau DM: Changes in use of opioid therapy after colon cancer diagnosis: a population-based study. Cancer Causes & Control 30(12): 1341-1350, December 2019.
Ibáñez-Sanz G, Garcia M, Milà N, Hubbard RA, Vidal C, Binefa G, Benito L, Moreno V on behalf of the ‘Adverse Effects on Colorectal Cancer Screening in Catalonia (EACC) Study’ working group: False-positive results in a population-based colorectal screening programme: cumulative risk over seven biennial FOBT screening rounds. Cancer Epidemiology, Biomarkers & Prevention 28(11): 1909-1916, November 2019.
Feld E, Harton J, Meropol NJ, Adamson B, Cohen A, Parikh RB, Galsky MD, Narayan VK, Christodouleas J, Vaughn D, Hubbard RA*, Mamtani R*: Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer. European Urology 76(4): 524-532, October 2019 Notes: *Equal contribution.
Chaiyachati KH, Liao JM, Weissman GE, Hubbard RA, Morgan AU, Buehler A, Shea JA, Armstrong KA: Gender differences in retention and promotion among generalists who graduated from research-intensive fellowships. Journal of Graduate Medical Education 11(5): 532-542, October 2019.
Demissei BG, Finkelman B, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan HK, Narayan V, Waxman AJ, Domchek SM, DeMichele A, Shah P, Clark AS, Bradbury A, Carver JR, Upshaw J, Armenian SH, Liu P, Ky B: Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. Cancer 125(16): 2762-2771, May 2019.
Pocobelli G, Yu O, Ziebell RA, Bowles EJA, Fujii MM, Sterret AT, Boggs JM, Chen L, Boudreau DM, Ritzwoller DP, Hubbard RA, Chubak JC: Use of antidepressants after colon cancer diagnosis and risk of recurrence. Psycho-Oncology 28(4): 750-758, April 2019 Notes: [epub ahead of print, DOI:10.1002/pon.5015]
Bowles EJA, Yu O, Ziebell R, Chen L, Boudreau D, Ritzwoller DP, Hubbard RA, Boggs J, Burnett-Hartman A, Sterrett A, Fujii M, Chubak J: Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study. BMC Cancer 19(1): 270, March 2019.
Noe MH, Rosenbach M, Hubbard RA, Cardones ARG, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Hughey LC, Kaffenberger BH, Kroshinsky D, Kwong BY, Miller DD, Mostaghimi A, Musiek A, Ortega Loayza AG, Sharon VR, Shinkai K, Summers EM, Wanat KA, Wetter DA, Worswick S, Margolis DJ, Gelfand JM, Micheletti RG: Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis— ABCD-10. JAMA Dermatology 155(4): 448-454, March 2019.
Chen Y, Wang J, Chubak J, Hubbard RA: Inflation of type I error rates due to differential misclassification in EHR-derived outcomes: Empirical illustration using breast cancer recurrence. Pharmacoepidemiology & Drug Safety 28(2): 264-268, February 2019.
Demissei BG, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Narayan V, Shah P, Waxman AJ, Domchek SM, Ky B: Cardiovascular function phenotypes in response to cardiotoxic breast cancer therapy. Journal of the American College of Cardiology 73(2): 248-249, February 2019.